普健生物(武汉)科技有限公司

首页 产品目录 产品目录(简版) 公司动态 企业认证 企业体检 公司相册 联系我们

武汉艾必赛生物有限公司推荐Recombinant FMDV (SAT-1) VP2 Protein, N-His,精品蛋白

发布人:普健生物(武汉)科技有限公司

发布日期:2026/4/14 17:30:17

链接:https://www.abinscience.cn/product/78/55015.html

名称:Recombinant FMDV (SAT-1) VP2 Protein, N-His

Accession号:A0A7L4XQ62

货号:VK164012

种属:Foot-and-mouth disease virus SAT 1

表达系统:E. coli

状态:Lyophilized

纯度:>90% as determined by SDS-PAGE.

蛋白长度:Asp285-Gln503

应用:ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

预测分子量 26.99 kDa

用途范围:仅用于科研

储存: Use  a manual defrost freezer and avoid repeated freeze thaw cycles. Store  at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months  from the date of receipt.

 

产品介绍:近期,我国首次发生输入性南非1型(SAT1)口蹄疫疫情,该血清型为非洲特有毒株,与我国长期流行的 O 型、A 型、亚洲 1 型等毒株在基因组、衣壳结构、抗原蛋白组成及表位构象上存在本质区别,不同血清型间无交叉免疫保护,现有常规疫苗无法提供有效保护。

Recombinant  FMDV (SAT-1) VP2 Protein, N-His (货号 VK164012)  是武汉艾必赛生物科技有限公司(abinScience)表达并纯化的一款高纯度重组蛋白。该蛋白对口蹄疫病毒(FMDV)SAT-1 血清型的 VP2  衣壳蛋白进行重组表达,其序列覆盖 Asp285 至 Gln503 区域,并在 C 端带有组氨酸(His)标签,预测分子量约为 26.99  kDa。本品采用大肠杆菌系统表达,通过镍柱亲和层析等方法纯化,经 SDS-PAGE 验证纯度高于 90%,为冻干粉剂型。

 

VP2  是口蹄疫病毒衣壳的关键结构蛋白之一,与 VP1、VP3  共同构成病毒的免疫原性基础,在病毒组装、宿主细胞识别及免疫应答诱导中扮演核心角色。本品具有高纯度与高特异性,经验证适用于酶联免疫吸附实验  (ELISA)、蛋白质免疫印迹 (Western Blot)、SDS-PAGE  分析,并可作为免疫原用于抗体开发,是进行口蹄疫病毒病原学研究、疫苗开发、诊断试剂制备及中和抗体筛选的重要核心试剂。

 

 

产品购买联系方式:027-87433958/17302791434

邮箱:info@abinscience.com 

图片.png


参考文献:A  Vaccine Strain of the A/ASIA/Sea-97 Lineage of Foot-and-Mouth Disease  Virus with a Single Amino Acid Substitution in the P1 Region That Is  Adapted to Suspension Culture Provides High Immunogenicity. PMID:  33805012
Capsid protein-encoding (P1) sequence of foot and mouth disease virus type Asia 1 ind 63/72. PMID: 10403702

Development of two rapid lateral flow test strips for detection of foot-and-mouth disease virus SAT 1 and SAT 3. PMID: 32898572
Unrecognized  circulation of SAT 1 foot-and-mouth disease virus in cattle herds  around Queen Elizabeth National Park in Uganda. PMID: 26739166
Development of vaccines toward the global control and eradication of foot-and-mouth disease. PMID: 21434805
Development  of reverse-transcriptase, real-time PCR assays to distinguish the  Southern African Territories (SAT) serotypes 1 and 3 and topotype VII of  SAT2 of Foot-and-Mouth Disease Virus. PMID: 36204292
Phylogenomics and molecular evolution of foot-and-mouth disease virus. PMID: 21448588
Genome Sequences of Four Foot-and-Mouth Disease Virus SAT 1 Topotype X Isolates from Cameroon. PMID: 31806747
Seroprevalence of foot-and-mouth disease virus in cattle herds raised in Maasai Mara ecosystem in Kenya. PMID: 32105863
Spatial pattern of foot-and-mouth disease virus serotypes in North Central Nigeria. PMID: 28507418
Foot-and-mouth disease virus serotype SAT1 in cattle, Nigeria. PMID: 28224715
The role of African buffalos (Syncerus caffer) in the maintenance of foot-and-mouth disease in Uganda. PMID: 21143994
Differentiation  of the seven serotypes of foot-and-mouth disease virus by reverse  transcriptase polymerase chain reaction. PMID: 9274816
Simple and rapid lateral-flow assay for the detection of foot-and-mouth disease virus. PMID: 19726619
Characterisation  of recent foot-and-mouth disease viruses from African buffalo (Syncerus  caffer) and cattle in Kenya is consistent with independent virus  populations. PMID: 25644407
First confirmation of foot and mouth  disease virus serotype SAT-1 in cattle and small ruminants in Ethiopia  in 2007/08. PMID: 23250672
Foot-and-mouth disease virus detection on a handheld real-time polymerase chain reaction platform. PMID: 31077564
Meta-analysis  of genetic diversity of VP1 gene of foot and mouth disease virus  serotypes prevalent in Bangladesh from 2010 to 2024. PMID: 41043698
Study on seroprevalence and serotyping of foot and mouth disease in Chad. PMID: 30964458
Characterization  of foot-and-mouth disease viruses (FMDVs) from Ugandan cattle outbreaks  during 2012-2013: evidence for circulation of multiple serotypes. PMID:  25664876
Serological and phylogenetic characterization of foot and  mouth disease viruses from Uganda during cross-sectional surveillance  study in cattle between 2014 and 2017. PMID: 31127983
Efficacy of a foot-and-mouth disease vaccine against a heterologous SAT1 virus challenge in goats. PMID: 32312581
Temporal  and Spatial Patterns and a Space-Time Cluster Analysis of  Foot-and-Mouth Disease Outbreaks in Ethiopia from 2010 to 2019. PMID:  35891538
Molecular Characterization of Foot-and-Mouth Disease Viruses Collected in Tanzania Between 1967 and 2009. PMID: 24460931
Within-Host  Viral Growth and Immune Response Rates Predict Foot-and-Mouth Disease  Virus Transmission Dynamics for African Buffalo. PMID: 39008835
Evaluation  of the solid phase competition ELISA for detecting antibodies against  the six foot-and-mouth disease virus non-O serotypes. PMID: 22561986
Differential Persistence of Foot-and-Mouth Disease Virus in African Buffalo Is Related to Virus Virulence. PMID: 26962214
Mutation pressure shapes codon usage in the GC-Rich genome of foot-and-mouth disease virus. PMID: 17768673
Effective  Diagnosis of Foot-And-Mouth Disease Virus (FMDV) Serotypes O and A  Based on Optical and Electrochemical Dual-Modal Detection. PMID:  34198783
A Simplified mAb-Based Antigen Detection Assay for Rapid Serotyping of Foot-and-Mouth Disease Virus. PMID: 40573352
Crystal structure of the 3C protease from Southern African Territories type 2 foot-and-mouth disease virus. PMID: 27168976
Serological  profile of foot-and-mouth disease in wildlife populations of West and  Central Africa with special reference to Syncerus caffer subspecies.  PMID: 26156024
Foot-and-mouth disease virus serotypes detected in  Tanzania from 2003 to 2010: conjectured status and future prospects.  PMID: 23327382
Investigation of foot-and-mouth disease outbreaks in the Mbala and Kazungula districts of Zambia. PMID: 25134173
Antibodies  against foot-and-mouth disease (FMD) virus in African buffalos  (Syncerus caffer) in selected National Parks in Uganda (2001-2003).  PMID: 20561289
Analysis of synonymous codon usage in foot-and-mouth disease virus. PMID: 20425142
Persistent  infection of African buffalo (Syncerus caffer) with SAT-type  foot-and-mouth disease viruses: rate of fixation of mutations, antigenic  change and interspecies transmission. PMID: 8757987

 

 

官方网址:【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

 

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司

武汉艾必赛生物技术有限公司成立于 2023 年,是 abinScience 在亚洲地区设立的官方全资子公司,全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。

依托严格的产品研发体系和国际化的质量管理标准,武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作,现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系,面向区域内科研机构、高校实验室与生物医药企业,提供稳定、高效、可信赖的产品与服务。

核心业务覆盖:
✅ 抗体产品(单抗、多抗、重组抗体等)
✅ 蛋白与多肽试剂(标签蛋白、功能蛋白等)
✅ 分子与细胞实验相关耗材
✅ 定制化研发服务(蛋白表达、抗体定制、亲和力成熟等)
✅ 科研供应链整合与项目配套支持

武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念,为亚太地区的生命科学研究持续注入高质量动能。

新闻图片1


相关新闻资讯

双特异性与三特异性抗体:多特异性抗体在癌症免疫治疗中的应用与进展

2026/04/15

自20世纪末单克隆抗体(mAbs)开启癌症免疫治疗新纪元以来,它们已成为临床治疗的重要支柱。然而,肿瘤抗原异质性、免疫逃逸以及药物耐药等挑战,推动了新一代多特异性抗体的快速发展。其中,双特异性抗体(BsAbs)能够同时结合两种不同抗原,而三特异性抗体(TsAbs)则将这一能力扩展到三个抗原靶点,从而实现更强的免疫重定向、信号阻断和肿瘤微环境调控。 双特异性抗体(BsAbs)和三特异性抗体(TsAb

曲妥珠单抗20年:从HER2靶点到抗体药物科研基石

2026/04/15

2026年,国际肿瘤学期刊《Annals of Oncology》刊发了一篇关于曲妥珠单抗(Trastuzumab)辅助治疗HER2阳性早期乳腺癌20周年的系统性综述。该综述基于全球多中心临床试验的超10年的随访数据、研究证据及20余年转化医学研究成果,对Trastuzumab 长期疗效、安全性进行了全面复盘,明确了其在靶向治疗中的基石地位,同时客观指出了该领域尚未解决的核心科学问题:除HER2过

免疫性血小板减少症(ITP)精准治疗机制解析与前沿靶向药物进展

2026/04/14

免疫性血小板减少症(Immune Thrombocytopenia, ITP)曾被称为“特发性血小板减少性紫癜”,是一种由于获得性免疫功能紊乱导致的自身免疫性疾病,临床主要表现为皮肤黏膜出血,严重者可发生颅内出血。的临床共识已将其定义为一种异质性极强的综合征,而非单一疾病。在流行病学层面,随着诊断技术的精确化,成人ITP的发病率在不同性别与年龄段中表现出明显的双峰分布,这暗示了不同年龄阶段可能存在